Forte Biosciences Inc (FBRX): Hedge Fund Ownership & Smart Money Signals (Q1 2026)

Q: Is it too late to buy Forte Biosciences Inc (FBRX) following the 2026 Q1 hedge fund 13F filings?

As of today, FBRX has moved -24.0% since the 2026 Q1 13F filing date (May 15, 2026), compared to +6.0% for the XLV sector ETF — an outperformance of -30.0%. Since the quarter end (March 31, 2026), FBRX gained -32.2% vs +4.9% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Forte Biosciences Inc (FBRX)

68 + Investors. Track Smart Money conviction in FBRX. See who's accumulating, reducing, or initiating positions.

Smart Money Signals — FBRX

Based on 68 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 7 quarters in a row

last 6Q

For 7 consecutive quarters, more hedge funds added FBRX than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

🏔️

At the ownership peak (100% of max)

100% of all-time peak

68 hedge funds hold FBRX right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.

🚀

Fast accumulation — +143% more funds vs a year ago

fund count last 6Q

+40 new funds entered over the past year (+143% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.

🟡

Slight buying edge — 58% buying

39 buying28 selling

Last quarter: 39 funds bought or added vs 28 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

➡️

Steady new buyers — ~18 new funds per quarter

new funds entering per quarter

Funds opening this position for the first time: 8 → 13 → 23 → 18. A stable flow of new institutional buyers suggests ongoing interest without signs of either acceleration or slowdown.

🔄

Mostly new holders — 63% entered in last year

■ 1% conviction (2yr+) ■ 35% medium ■ 63% new

Only 1 funds (1%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.

🚀

Acceleration phase — new buyers rushing in

5 → 8 → 13 → 23 → 18 new funds/Q

New funds entering each quarter: 8 → 13 → 23 → 18. The pace of institutional discovery is accelerating sharply. This is the 'hot idea' phase — the thesis is being passed from fund to fund. You are not late — the accumulation wave is still building.

🌱

Early stage — 71% of holders entered in last year

■ 1% veterans ■ 27% 1-2yr ■ 71% new

Of 70 current holders: 50 (71%) entered in the past year, only 1 (1%) are 2+ year veterans. This is an early-phase institutional idea — still being discovered. High upside potential if the thesis plays out, but thin conviction base.

✅

Strong quality — 25% AUM from major funds

25% from top-100 AUM funds

22 of 67 holders rank in the top 100 by AUM, accounting for 25% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

6.3

out of 10

Moderate Exit Risk

Exit risk score 6.3/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Metric	All 13F Filers (2026 Q1)	Prior (2025 Q4)	Change
Funds Holding	68	57	19.3%
13F Shares	14M	12M	17.83%
Total Value	$349M	$315M	10.89%
New Positions	18	23	-5
Increased Positions	20	21	-1
Closed Positions	7	7	-
Reduced Positions	20	7	+13
Total Calls	2	1	100.0%
Total Puts	1	0	100%
PUT/CALL Ratio	0.5	0.0	Bullish

Metric

All 13F Filers (2026 Q1)

Prior (2025 Q4)

Change

Funds Holding

19.3%

13F Shares

14M

12M

17.83%

Total Value

$349M

$315M

10.89%

New Positions

-5

Increased Positions

-1

Closed Positions

Reduced Positions

+13

Total Calls

100.0%

Total Puts

100%

PUT/CALL Ratio

0.5

0.0

Bullish

Institutional Holders (2026 Q1)

68 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in FBRX. Verified SEC 13F-HR filings.

QUARTER:

FILTER:All New Added To Reduced No Change | Overweight >5%

Top 25 FBRX holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
#	Investor	% of Portfolio	Shares	Mkt Value
1	Cable Car Capital, LP	3.58%	400,000	$10.4M
2	MPM BioImpact LLC	2.00%	1,000,682	$25.9M
3	Affinity Asset Advisors, LLC	1.35%	1,011,890	$26.2M
4	Sphera Funds Management LTD.	0.76%	184,984	$4.8M
5	Orbimed Advisors LLC	0.61%	1,196,955	$31.0M
6	AWM Investment Company, Inc.	0.57%	200,000	$5.2M
7	Stempoint Capital LP	0.29%	58,020	$1.5M
8	Ikarian Capital, LLC	0.25%	118,972	$3.1M
9	Integral Health Asset Management, LLC	0.19%	150,000	$3.9M
10	Fred Alger Management, LLC	0.14%	1,273,965	$33.0M
11	Weil Company, Inc.	0.14%	24,765	$641K
12	Federated Hermes, INC.	0.07%	1,765,516	$45.7M
13	Persistent Asset Partners Ltd	0.07%	6,744	$175K
14	Mangrove Partners IM, LLC	0.05%	25,706	$666K
15	J. Goldman & Co LP	0.04%	54,174	$1.4M
16	Adage Capital Partners GP, L.L.C.	0.04%	950,000	$24.6M
17	Woodline Partners LP	0.03%	331,987	$8.6M
18	AlphaQuest LLC	0.03%	18,804	$513K
19	683 Capital Management, LLC	0.03%	20,000	$518K
20	Janus Henderson Group plc	0.02%	1,188,060	$30.8M
21	Trexquant Investment LP	0.01%	73,651	$1.9M
22	Candriam S.C.A.	0.01%	84,803	$2.2M
23	Sig Brokerage, LP	0.01%	10,000	$259K
24	Quadrature Capital Ltd	0.01%	18,622	$482K
25	Engineers Gate Manager LP	0.01%	16,427	$425K

Investor	Ownership History	% of Portfolio	Prev %	Rank	Conviction	Avg Buy Price	13F Score™ 3Y / 7Y	Sell Timing	Shares	Mkt Value	Change	Change %	Source	Quarter	Filed

Frequently Asked Questions — Forte Biosciences Inc (FBRX)

What does the Smart Money Trend signal show for FBRX?

Buying streak — 7 quarters in a row: For 7 consecutive quarters, more hedge funds added FBRX than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for FBRX?

Slight buying edge — 58% buying: Last quarter: 39 funds bought or added vs 28 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for FBRX holders?

Strong quality — 25% AUM from major funds: 22 of 67 holders rank in the top 100 by AUM, accounting for 25% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

How long have hedge funds held FBRX?

Mostly new holders — 63% entered in last year: Only 1 funds (1%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.

Is it too late to buy Forte Biosciences Inc (FBRX) following the 2026 Q1 hedge fund 13F filings?

As of today, FBRX has moved -24.0% since the 2026 Q1 13F filing date (May 15, 2026), compared to +6.0% for the XLV sector ETF — an outperformance of -30.0%. Since the quarter end (March 31, 2026), FBRX has gained -32.2% vs +4.9% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Market Cap	--
Enterprise Value	--
Trailing P/E	--
Forward P/E	--
PEG Ratio (5yr expected)	--
Price/Sales (ttm)	--
Price/Book (mrq)	--
Enterprise Value/Revenue	--
Enterprise Value/EBITDA	--
Beta (5Y Monthly)	--
Short Ratio (Days to Cover)	--
Short % of Float	--

Profit Margin	--
Return on Assets (ttm)	--
Return on Equity (ttm)	--

Revenue (ttm)	--
Net Income Avi to Common (ttm)	--
Diluted EPS (ttm)	--
Total Cash (mrq)	--
Total Debt/Equity (mrq)	--
Levered Free Cash Flow (ttm)	--

Forte Biosciences Inc (FBRX)

Smart Money Signals — FBRX

Buying streak — 7 quarters in a row

At the ownership peak (100% of max)

Fast accumulation — +143% more funds vs a year ago

Slight buying edge — 58% buying

Steady new buyers — ~18 new funds per quarter

Mostly new holders — 63% entered in last year

Acceleration phase — new buyers rushing in

Early stage — 71% of holders entered in last year

Strong quality — 25% AUM from major funds

Institutional Sentiment Summary — FBRX

Hedge Fund Ownership: FBRX

Market Analysis: FBRX

Analyst Price Targets

Analyst Recommendations

Stock Performance

Company Profile: FBRX

Is It Too Late to Buy Forte Biosciences Inc (FBRX) Based on Hedge Fund 13F Filings?

Hedge Fund Positioning: FBRX

Statistics: FBRX

Valuation Measures Data as of: --

Financial Highlights

Institutional Holders (2026 Q1)

Frequently Asked Questions — Forte Biosciences Inc (FBRX)

Welcome to 13Foresight!